[ March 2007 ]
ASAQ Launch Sanofi -aventis and DNDi launched ASAQ, the new fixed-dose combination of
artesunate (AS) and amodiaquine (AQ), which is now available in 21 countries
throughout sub-Saharan Africa (June 08). ASAQ, the first drug developed by DNDi,
is an innovative product to treat malaria that is adapted to the needs of patients of all ages,
simple to use, accessible as a non patented drug, and available at an affordable price.
Click here to read more